- Home
- ABTS vs PPBT Comparison
ABTS vs PPBT Comparison
Compare ABTS & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABTS
- PPBT
- Stock Information
- Founded
- ABTS 2010
- PPBT 2010
- Country
- ABTS Hong Kong
- PPBT Israel
- Employees
- ABTS N/A
- PPBT N/A
- Industry
- ABTS Computer Software: Programming Data Processing
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- ABTS Technology
- PPBT Health Care
- Exchange
- ABTS Nasdaq
- PPBT Nasdaq
- Market Cap
- ABTS 9.8M
- PPBT 6.2M
- IPO Year
- ABTS N/A
- PPBT N/A
- Fundamental
- Price
- ABTS $5.16
- PPBT $2.48
- Analyst Decision
- ABTS
- PPBT Strong Buy
- Analyst Count
- ABTS 0
- PPBT 1
- Target Price
- ABTS N/A
- PPBT $33.00
- AVG Volume (30 Days)
- ABTS 46.4K
- PPBT 18.5K
- Earning Date
- ABTS 08-16-2025
- PPBT 08-15-2025
- Dividend Yield
- ABTS N/A
- PPBT N/A
- EPS Growth
- ABTS N/A
- PPBT N/A
- EPS
- ABTS N/A
- PPBT N/A
- Revenue
- ABTS $6,711,225.00
- PPBT N/A
- Revenue This Year
- ABTS N/A
- PPBT N/A
- Revenue Next Year
- ABTS N/A
- PPBT N/A
- P/E Ratio
- ABTS N/A
- PPBT N/A
- Revenue Growth
- ABTS 299.11
- PPBT N/A
- 52 Week Low
- ABTS $1.35
- PPBT $2.00
- 52 Week High
- ABTS $14.10
- PPBT $13.95
- Technical
- Relative Strength Index (RSI)
- ABTS 58.41
- PPBT 52.43
- Support Level
- ABTS $4.11
- PPBT $2.35
- Resistance Level
- ABTS $6.08
- PPBT $2.58
- Average True Range (ATR)
- ABTS 0.58
- PPBT 0.12
- MACD
- ABTS 0.11
- PPBT 0.01
- Stochastic Oscillator
- ABTS 63.92
- PPBT 68.75
About ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations. The group has its subsidiaries in USA, China, Canada and Hong Kong.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.